<DOC>
	<DOCNO>NCT00754104</DOCNO>
	<brief_summary>Study ABT-869 Combination Tarceva Subjects Solid Tumors</brief_summary>
	<brief_title>Study ABT-869 Combination With Tarceva Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Subject must histologically cytologically confirm nonhematologic malignancy . Subject must ECOG Score 02 . Adequate organ function . Subject receive targeted VEGF/PDGF therapy ( tyrosine kinase inhibitor ) therapy . Prior Avastin allow . Subject untreated brain meningeal metastasis . History great 10 % weight loss . Has clinically relevant hemoptysis . Subject proteinuria CTC grade &gt; 1 . Must radiation therapy major surgery within 21 day study day 1 . The subject currently exhibit symptomatic persistent , uncontrolled hypertension define diastolic blood pressure ( DBP ) &gt; 100 mmHg systolic blood pressure ( SBP ) &gt; 150 mmHg . Subjects may rescreened blood pressure show control without intervention . The subject document leave ventricular ejection fraction ( LVEF ) &lt; 50 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>